Adecatumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Adecatumumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target EpCAM
Clinical data
Legal status
?
Identifiers
CAS number 503605-66-1 N
ATC code None
Chemical data
Formula C6552H10080N1740O2052S46 
Mol. mass 147.5 kDa
 N (what is this?)  (verify)

Adecatumumab (MT201) is a recombinant human monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326).

Adecatumumab has been used in clinical studies of treatment in prostate[1] and breast cancers.[2]

References[edit]

  1. ^ Oberneder R, Weckermann D, Ebner B, et al. (October 2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". Eur. J. Cancer 42 (15): 2530–8. doi:10.1016/j.ejca.2006.05.029. PMID 16930989. 
  2. ^ Prang N, Preithner S, Brischwein K, et al. (January 2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". Br. J. Cancer 92 (2): 342–9. doi:10.1038/sj.bjc.6602310. PMC 2361858. PMID 15655555.